drugset / Trial / NCT01343303

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-39439335 in Patients With Osteoarthritis

NCT01343303

Phase 1 Completed 43 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety of multiple oral doses of JNJ-39439335 and to assess how JNJ-39439335 is absorbed (taken in), distributed, metabolized (broken down), and eliminated from the body (referred to as pharmacokinetics) in osteoarthritis patients. This study will also assess the effectiveness of JNJ-39439335 on pain.

Timeline

Start
2011-03
Primary completion
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MAVATREP Small molecule 10 mg Oral
Subject MAVATREP Small molecule 25 mg Oral
Subject Naproxen Small molecule 500 mg Oral

Indications